Stocks · News reference
CEL-SCI shares are trading lower. The company announced the launch of its global Confirmatory Registration Study of Multikine as a neoadjuvant treatment for locally advanced primary head and neck cancer.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CEL-SCI Q3 EPS $(0.47) Up From $(1.36) YoY
CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.47) per share. This is a 65.44 percent increase over losses of $(1.36) per share from the same period last year.
CEL-SCI Announces Publication Of Its Study, 'A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival In Oral Cancer Patients With Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role Of Tumor PD-L1 Expression' In Journal Oral Oncology
The published article identified low and zero (0%) PD-L1 expression and no lymph node involvement as biomarkers for selecting patients most likely to benefit from Multikine pre-surgery treatmentStudy concludes Multikine
CEL-SCI Announces Multikine Phase 3 Data Accepted For Publication In Oral Oncology, Citing 73% Five-Year Survival vs. 45% For Standard Of Care In Low PD-L1 Head And Neck Cancer